- Home
- RCEL vs KRRO Comparison
RCEL vs KRRO Comparison
Compare RCEL & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- KRRO
- Stock Information
- Founded
- RCEL N/A
- KRRO 2014
- Country
- RCEL United States
- KRRO United States
- Employees
- RCEL N/A
- KRRO N/A
- Industry
- RCEL Medical/Dental Instruments
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- KRRO Health Care
- Exchange
- RCEL Nasdaq
- KRRO Nasdaq
- Market Cap
- RCEL 308.6M
- KRRO 281.2M
- IPO Year
- RCEL N/A
- KRRO 2019
- Fundamental
- Price
- RCEL $9.75
- KRRO $26.29
- Analyst Decision
- RCEL Buy
- KRRO Strong Buy
- Analyst Count
- RCEL 5
- KRRO 7
- Target Price
- RCEL $17.25
- KRRO $133.83
- AVG Volume (30 Days)
- RCEL 191.4K
- KRRO 61.9K
- Earning Date
- RCEL 02-13-2025
- KRRO 03-25-2025
- Dividend Yield
- RCEL N/A
- KRRO N/A
- EPS Growth
- RCEL N/A
- KRRO N/A
- EPS
- RCEL N/A
- KRRO N/A
- Revenue
- RCEL $64,251,000.00
- KRRO N/A
- Revenue This Year
- RCEL $62.11
- KRRO N/A
- Revenue Next Year
- RCEL $31.19
- KRRO N/A
- P/E Ratio
- RCEL N/A
- KRRO N/A
- Revenue Growth
- RCEL 28.14
- KRRO N/A
- 52 Week Low
- RCEL $7.51
- KRRO $26.23
- 52 Week High
- RCEL $18.93
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- RCEL 50.10
- KRRO 29.17
- Support Level
- RCEL $8.37
- KRRO $28.90
- Resistance Level
- RCEL $11.25
- KRRO $40.68
- Average True Range (ATR)
- RCEL 0.55
- KRRO 2.26
- MACD
- RCEL 0.22
- KRRO -0.36
- Stochastic Oscillator
- RCEL 47.92
- KRRO 0.42
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.